MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 02:17 am
Share
MEDIPOST Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 13,231.61 million compared to KRW 11,841.89 million a year ago. Net loss was KRW 29.23 million compared to KRW 5,179.3 million a year ago. Basic loss per share from continuing operations was KRW 2 compared to KRW 334 a year ago. Diluted loss per share from continuing operations was KRW 2 compared to KRW 334 a year ago. Basic loss per share was KRW 2 compared to KRW 334 a year ago.
For the nine months, sales was KRW 1,657.52 million compared to KRW 1,863.43 million a year ago. Net loss was KRW 5,338.86 million compared to KRW 1,873.25 million a year ago. Basic loss per share from continuing operations was KRW 333 compared to KRW 121 a year ago. Diluted loss per share from continuing operations was KRW 333 compared to KRW 121 a year ago. Basic loss per share was KRW 333 compared to KRW 121 a year ago.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
